Alumis Inc. Common Stock
Financials
Valuation Metrics
Alumis Inc. Common Stock's Market Cap is $997M. At end of 2025 it was $1.02B. Ranked #2473 of 3,121 in US market (top 79%), #1018 of 1,463 on NASDAQ (top 70%), #190 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 71%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $997M | US#2,473/3,121 Sec#190/266 |
| Revenue | $7M | US#2,842/3,121 Sec#174/266 |
| Net Income | $-439M | US—/3,121 Sec—/266 |
| Total Assets | $561M | US#2,727/3,121 Sec#150/266 |
| Net Assets | $452M | US#2,301/3,121 Sec#120/266 |
| Employees | 226 | US#2,476/3,121 Sec#127/266 |
| Value | ||
| P/B | 2.21x | US#1,369/3,121 Sec#60/266 |
| P/S | 134.76x | US#2,955/3,121 Sec#183/266 |
| FCF Yield | -35.29% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -97.08% | US#2,788/3,121 Sec#201/266 |
| ROA | -78.30% | US#3,044/3,121 Sec#246/266 |
| Op. Margin | -6204.39% | US#2,865/3,121 Sec#184/266 |
| Revenue Growth | -63.11% | US#2,754/3,121 Sec#170/266 |
| Financial Health | ||
| Debt Ratio | 23.99% | US#268/3,121 Sec#90/266 |
| Total Debt | $36M | US#2,669/3,121 Sec#170/266 |
| FCF | $-352M | US#2,869/3,121 Sec#241/266 |
| Cash | $64M | US#2,468/3,121 Sec#210/266 |
| Current Ratio | 6.74x | US#370/3,121 Sec#116/266 |
| Performance | ||
| 1Y Return | 89.35% | US#259/3,121 Sec#70/266 |
| 1M Return | -68.57% | US#3,115/3,121 Sec#266/266 |
| From 52W High | -75.06% | US#3,049/3,121 Sec#250/266 |
| 1Y MDD | -74.19% | US#3,007/3,121 Sec#244/266 |
| Trading | ||
| Volume | 3,412,815 shares | US#503/3,121 Sec#43/266 |
| Trading Value | $27M | US#1,684/3,121 Sec#130/266 |
| Per Share | ||
| EPS | $-3.44 | US—/3,121 Sec—/266 |
| BPS | $3.55 | US#2,417/3,121 Sec#152/266 |
Company Info
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.